BiotechTube

Leuprorelin Acetate

Phase 3Active
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Metastases

Conditions

Metastases

Trial Timeline

Jul 1, 2011 → Sep 1, 2027

NCT ID
NCT01442246

About Leuprorelin Acetate

Leuprorelin Acetate is a phase 3 stage product being developed by Astellas Pharma for Metastases. The current trial status is active. This product is registered under clinical trial identifier NCT01442246. Target conditions include Metastases.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (2)

NCT IDPhaseStatus
NCT01442246Phase 3Active
NCT00378690Phase 3Completed

Competing Products

20 competing products in Metastases

See all competitors
ProductCompanyStageHype Score
LY2780301Eli LillyPhase 1
33
Abemaciclib + Endocrine therapyEli LillyPhase 1/2
41
Patritumab deruxtecanDaiichi SankyoPhase 2
52
Trastuzumab deruxtecanDaiichi SankyoPhase 2
52
Denosumab + Zoledronic AcidDaiichi SankyoPhase 3
77
Pembrolizumab + LenvatinibEisaiPhase 2
52
ALIMTA + folic acid + multi-vitaminsEli LillyPhase 1
33
MerestinibEli LillyPhase 1
33
LY2584702 + Erlotinib + EverolimusEli LillyPhase 1
33
Veliparib + PlaceboAbbViePhase 2
52
temozolomideMerckPhase 2
52
VorinostatMerckPhase 1
33
PembrolizumabMerckPhase 2
52
EMD 525797MerckPhase 1
33
TemozolomideMerckPhase 2
52
cabazitaxel + lapatinibNovartisPhase 2
52
BKM120 + capecitabine + TrastuzumabNovartisPhase 2
52
Zoledronic acidNovartisPhase 3
77
zoledronic acidNovartisPhase 1
33
capecitabine + lapatinib + trastuzumabNovartisPhase 3
77

Other Products from Astellas Pharma

Tacrolimus, Prograf®Approved
85
micafungin + voriconazoleApproved
85
mirabegron + solifenacinApproved
85
Zolpidem (Myslee®) + placeboApproved
85
TacrolimusApproved
85